Obeticholic Acid for Non-alcoholic Fatty Liver Disease (REGENERATE Trial)

"100 locations, including the Liver Wellness Center in Little Rock, UF Hepatology Research at CTRB in Gainesville, and Mayo Clinic in Rochester are participating."

"As it stands, there are 7 ongoing studies that involve Obeticholic Acid. Out of these clinical trials, 2 are still in Phase 3. The majority of research regarding Obeticholic Acid takes place in Changchun, Jilin; however, there are a total of 424 research sites for this medication."

"This particular trial is no longer accepting patients. The study was first announced on September 22nd, 2015 and the most recent update was November 1st, 2022. There are currently 244 other trials recruiting participants with non alcoholic steatohepatitis (nash) and 7 for Obeticholic Acid if you are interested in participating in a clinical trial."

"Unfortunately, this study is not currently searching for patients. According to the clinical trial's website, it was initially posted on September 22nd, 2015 and updated November 1st, 2020. There are presently 244 studies actively enrolling patients with non alcoholic steatohepatitis (nash) and 7 trials for Obeticholic Acid actively recruiting participants."

"This study is taking in individuals that are above the age of 18 and younger than 85."

"Obeticholic Acid has been studied in multiple Phase 3 clinical trials, meaning that there is some data supporting its efficacy and safety. Our team at Power estimates the safety of Obeticholic Acid to be a 3 on a scale from 1 to 3."

"The inclusion criteria for this clinical trial requires that patients have non alcoholic steatohepatitis (nash) and are between 18-85 years old. A total of 2480 participants will be accepted into the study."

"Intercept Pharmaceuticals first sponsored a study for Obeticholic Acid in 2015, which then led to the drug receiving Phase 3 approval that same year. Since then, there have been 7 active clinical trials involving the medication across 142 cities and 31 countries."